Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2003 1
2004 5
2005 7
2006 10
2007 13
2008 11
2009 8
2010 10
2011 13
2012 17
2013 14
2014 5
2015 13
2016 10
2017 13
2018 41
2019 20
2020 18
2021 18
2022 18
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Results by year

Filters applied: . Clear all
Page 1
Improved overall survival in patients with high-grade serous ovarian cancer is associated with CD16a+ immunologic neighborhoods containing NK cells, T cells and macrophages.
Nersesian S, Arseneau RJ, Mejia JP, Lee SN, Westhaver LP, Griffiths NW, Grantham SR, Meunier L, Communal L, Mukherjee A, Mes-Masson AM, Arnason T, Nelson BH, Boudreau JE. Nersesian S, et al. Among authors: mes masson am. Front Immunol. 2024 Jan 22;14:1307873. doi: 10.3389/fimmu.2023.1307873. eCollection 2023. Front Immunol. 2024. PMID: 38318505 Free PMC article.
Methylene Blue Metabolic Therapy Restrains In Vivo Ovarian Tumor Growth.
da Veiga Moreira J, Nleme N, Schwartz L, Leclerc-Desaulniers K, Carmona E, Mes-Masson AM, Jolicoeur M. da Veiga Moreira J, et al. Among authors: mes masson am. Cancers (Basel). 2024 Jan 13;16(2):355. doi: 10.3390/cancers16020355. Cancers (Basel). 2024. PMID: 38254843 Free PMC article.
A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinoma.
Brassard J, Hughes MR, Dean P, Hernaez DC, Thornton S, Banville AC, Smazynski J, Warren M, Zhang K, Milne K, Gilks CB, Mes-Masson AM, Huntsman DG, Nelson BH, Roskelley CD, McNagny KM. Brassard J, et al. Among authors: mes masson am. Front Oncol. 2023 Dec 21;13:1286754. doi: 10.3389/fonc.2023.1286754. eCollection 2023. Front Oncol. 2023. PMID: 38188285 Free PMC article.
Molecular landscape and functional characterization of centrosome amplification in ovarian cancer.
Sauer CM, Hall JA, Couturier DL, Bradley T, Piskorz AM, Griffiths J, Sawle A, Eldridge MD, Smith P, Hosking K, Reinius MAV, Morrill Gavarró L, Mes-Masson AM, Ennis D, Millan D, Hoyle A, McNeish IA, Jimenez-Linan M, Martins FC, Tischer J, Vias M, Brenton JD. Sauer CM, et al. Among authors: mes masson am. Nat Commun. 2023 Oct 16;14(1):6505. doi: 10.1038/s41467-023-41840-3. Nat Commun. 2023. PMID: 37845213 Free PMC article.
Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy.
Henault D, Stephen D, St-Hilaire PA, Messaoudi N, Vandenbroucke-Menu F, Simoneau E, Rong Z, Plasse M, Létourneau R, Roy A, Dagenais M, Lapointe R, Nguyen B, Mes-Masson AM, Soucy G, Turcotte S. Henault D, et al. Among authors: mes masson am. Oncoimmunology. 2023 Sep 14;12(1):2253642. doi: 10.1080/2162402X.2023.2253642. eCollection 2023. Oncoimmunology. 2023. PMID: 37720689 Free PMC article.
GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer.
Galan A, Papaluca A, Nejatie A, Matanes E, Brahimi F, Tong W, Hachim IY, Yasmeen A, Carmona E, Klein KO, Billes S, Dawod AE, Gawande P, Jeter AM, Mes-Masson AM, Greenwood CMT, Gotlieb WH, Saragovi HU. Galan A, et al. Among authors: mes masson am. Front Oncol. 2023 Apr 14;13:1134763. doi: 10.3389/fonc.2023.1134763. eCollection 2023. Front Oncol. 2023. PMID: 37124505 Free PMC article.
Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases.
Alenezi WM, Fierheller CT, Serruya C, Revil T, Oros KK, Subramanian DN, Bruce J, Spiegelman D, Pugh T, Campbell IG, Mes-Masson AM, Provencher D, Foulkes WD, Haffaf ZE, Rouleau G, Bouchard L, Greenwood CMT, Ragoussis J, Tonin PN. Alenezi WM, et al. Among authors: mes masson am. Front Oncol. 2023 Mar 8;13:1111191. doi: 10.3389/fonc.2023.1111191. eCollection 2023. Front Oncol. 2023. PMID: 36969007 Free PMC article.
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
Sauriol A, Carmona E, Udaskin ML, Radulovich N, Leclerc-Desaulniers K, Rottapel R, Oza AM, Lheureux S, Provencher DM, Mes-Masson AM. Sauriol A, et al. Among authors: mes masson am. Sci Rep. 2023 Feb 27;13(1):3334. doi: 10.1038/s41598-023-30081-5. Sci Rep. 2023. PMID: 36849518 Free PMC article.
Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene.
Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN. Fierheller CT, et al. Among authors: mes masson am. Genes (Basel). 2023 Jan 20;14(2):277. doi: 10.3390/genes14020277. Genes (Basel). 2023. PMID: 36833203 Free PMC article.
266 results